Dimopoulos, M.A.

patient myeloma therapy treatment lenalidomide study dexamethasone thalidomide bortezomib university serum cancer disease blood trial survival factor response combination hospital group table myeloma patients phase signi progression len /dex department neuropathy level month marker leukemia result high-dose regimen grade chain hematology melphalan agent transplantation randomized light protein prednisone recommendation oncol event ef ficacy institute marrow reduction chemotherapy cell transplantation signi ficantly outcome guideline effect high-dose therapy center incidence prophylaxi analysis bisphosphonate palumbo risk factors novel cyclophosphamide novel agents stage urine mayo clinic zoledronic acid celgene mm patients myeloma bone disease transplant lesion dimopoulo